Literature DB >> 9461239

Abnormal regulation of transforming growth factor-beta receptors on vascular smooth muscle cells from spontaneously hypertensive rats by angiotensin II.

N Fukuda1, W Y Hu, A Kubo, M Endoh, H Kishioka, C Satoh, M Soma, Y Izumi, K Kanmatsuse.   

Abstract

The effects of angiotensin II (Ang II) on the expression and characteristics of transforming growth factor-beta (TGF-beta) receptors on vascular smooth muscle cells (VSMC) from Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR) were investigated. TGF-beta-induced stimulation of DNA synthesis by VSMC from WKY rats was abolished with Ang II, whereas basal and TGF-beta-stimulated DNA synthesis by VSMC from SHR was increased with Ang II. Ang II stimulated DNA synthesis by VSMC from WKY rats in the presence but not in the absence of neutralizing antibody to TGF-beta1. Antibody to TGF-beta1 enhanced the stimulatory effect of Ang II on DNA synthesis by VSMC from SHR. Ang II increased the specific binding of TGF-beta to VSMC from WKY rats by increasing both the expression of the lower-affinity of TGF-beta receptors as well as the total number of TGF-beta binding sites. In contrast, VSMC from SHR showed a higher affinity and number of TGF-beta receptors in the absence of Ang II than did cells from WKY rats, and these parameters were not affected by Ang II. Ang II increased the expression of TGF-beta type I receptor mRNA in VSMC from WKY rats but had no effect of TGF-beta receptor type I or II mRNA in VSMC from SHR, which predominantly express the type II receptor. These results indicate that an increase in the expression of the TGF-beta type I receptor by Ang II may facilitate the ability of endogenous TGF-beta to counteract the stimulatory effect of Ang II on growth in VSMC from WKY rats, whereas endogenous TGF-beta induced by Ang II cannot counteract the growth-promoting action of Ang II in VSMC from SHR. The abnormal regulation of TGF-beta receptors by Ang II may be associated with the exaggerated growth of VSMC from SHR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9461239     DOI: 10.1161/01.hyp.31.2.672

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension.

Authors:  Steven D Crowley; Young-Soo Song; Gregory Sprung; Robert Griffiths; Matthew Sparks; Ming Yan; James L Burchette; David N Howell; Eugene E Lin; Benson Okeiyi; Johannes Stegbauer; Yanqiang Yang; Pierre-Louis Tharaux; Phillip Ruiz
Journal:  Hypertension       Date:  2009-12-07       Impact factor: 10.190

2.  A prospective study of hypertension and risk of uterine leiomyomata.

Authors:  Renée Boynton-Jarrett; Janet Rich-Edwards; Susan Malspeis; Stacey A Missmer; Rosalind Wright
Journal:  Am J Epidemiol       Date:  2005-04-01       Impact factor: 4.897

3.  The Relationship between the Transforming Growth Factor β1 T29C Gene Polymorphism and Left Ventricular Geometry and Function in Hypertensive Subjects.

Authors:  Rosario Scaglione; Christiano Argano; Giovanni Duro; Tiziana Di Chiara; Domenico Nuzzo; Daniela Colomba; Maria Cristina Fiore; Salvatore Corrao; Giuseppe Licata
Journal:  Int J Hypertens       Date:  2010-03-23       Impact factor: 2.420

4.  Increased Complement 3 With Suppression of miR-145 Induces the Synthetic Phenotype in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats.

Authors:  Lan Chen; Noboru Fukuda; Tomoyasu Otsuki; Sho Tanaka; Yoshihiro Nakamura; Hiroki Kobayashi; Taro Matsumoto; Masanori Abe
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

5.  Reduction in skeletal muscle fibrosis of spontaneously hypertensive rats after laceration by microRNA targeting angiotensin II receptor.

Authors:  Roberta Sessa Stilhano; Vivian Yochiko Samoto; Leonardo Martins Silva; Gustavo José Pereira; Adolfo Garcia Erustes; Soraya Soubhi Smaili; Sang Won Han
Journal:  PLoS One       Date:  2017-10-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.